Platinum(IV) Complex Overcoming Cisplatin Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platinum-based chemotherapeutic compounds, such as cisplatin, are limited by severe side effects and the development of chemoresistance in cancer treatment, necessitating the need for more effective and resistant-free alternatives.
Innovation Solution
A novel platinum(IV) complex with a specific structure, comprising an aryl-comprising moiety and electron donor ligands, is developed, which is synthesized through a method involving platinum complex precursors and N-hydroxysuccinimide esters, offering superior cytotoxic activity against cancer cells, including cisplatin-resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based chemotherapeutic compounds (cisplatin, carboplatin, oxaliplatin) are used for cancer treatment, then cancer cells can be targeted and DNA crosslinking can be achieved, but severe side effects and chemoresistance occur
Solution Approach 1:
The patent changes the oxidation state parameter of platinum from +2 (in cisplatin, carboplatin, oxaliplatin) to +4, creating a different electronic configuration and reactivity profile that overcomes chemoresistance while maintaining DNA-binding capability. This parameter change allows the compound to bypass resistance mechanisms developed against traditional platinum drugs.
Solution Approach 2:
The patent creates a composite molecular structure combining platinum(IV) center with specific organic ligands including aryl-comprising moieties and electron-donor ligands. This composite approach integrates multiple functional components that work synergistically to enhance cytotoxicity against resistant cancer cells while reducing harmful side effects compared to conventional platinum compounds.
2Productivity
If conventional platinum compounds are administered to achieve therapeutic effect, then DNA binding and apoptosis triggering occur, but the treatment is limited by severe side effects
Solution Approach 1:
The patent modifies the platinum oxidation state from +2 to +4, fundamentally changing the compound's reactivity, stability, and biological interaction profile. This parameter change enables the drug to maintain therapeutic effectiveness while reducing side effects, as the platinum(IV) complex exhibits different cellular uptake mechanisms and DNA-binding kinetics compared to platinum(II) compounds.
Solution Approach 2:
The patent introduces specific local structural features including aryl-comprising moieties and electron-donor ligands positioned around the platinum(IV) center. These localized structural modifications create specific interaction zones that enhance target specificity and reduce off-target toxicity, thereby improving the therapeutic index by separating effective concentration from toxic concentration.
3Reliability
If platinum-based chemotherapeutic compounds are used to treat cancer, then DNA crosslinking is achieved, but intrinsic and acquired resistances significantly limit clinical use
Solution Approach 1:
The patent changes the oxidation state from +2 to +4, creating a fundamentally different chemical species that bypasses resistance mechanisms evolved against platinum(II) compounds. Cancer cells that have developed resistance to cisplatin, carboplatin, or oxaliplatin remain sensitive to platinum(IV) complexes due to differences in cellular entry pathways, activation mechanisms, and DNA-binding kinetics.
Solution Approach 2:
The patent inverts the conventional approach by using a higher oxidation state (Pt(IV)) instead of the traditional lower oxidation state (Pt(II)). This inversion strategy exploits the fact that resistance mechanisms against Pt(II) compounds do not confer protection against Pt(IV) complexes, thereby providing a novel therapeutic avenue for resistant cancers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platinum(IV) complex demonstrates high cytotoxic activity with nanomolar IC50 values and reduced resistance factors, effectively treating cancer cells, including those resistant to cisplatin, with improved safety profiles compared to existing platinum-based therapies.
Implementation Method 1
these compounds are associated with severe side effects. In addition, both intrinsic and acquired resistances against these compounds have been observed after the treatment with these compounds which further significantly limits their clinical use.
Implementation Method 2
Said method comprises linking a platinum complex precursor comprising a structure of Formula (XI) with an aryl-comprising moiety R to form the platinum(IV) complex
Data Source
AI summary
Platinum(IV) complexes especially suitable for antitumor therapy and methods for their preparation. Further provided is a method for treating a subject, in particular a human, suffering from a disease including administering a platinum(IV) complex of the present invention, which disease is especially preferably but not exclusively a cancer. Further provided is a method of inhibiting the growth of tumor cells by contacting the cells with a platinum(IV) complex of the present invention and a pharmaceutical composition including a platinum(IV) complex of the present invention. The platinum(IV) complexes of the present invention represent a novel class of platinum anticancer prodrugs for the treatment of diseases especially of cancer. The platinum(IV) complexes of the present invention exhibit advantageously high cytotoxic activity in various cancer types superior to commonly used platinum-based complexes. In addition, the complexes proved to be highly effective even against cisplatin-resistant cancers.